ALK and non-small cell lung carcinoma: In fact, the studies have shown that the combination of anti-TIGIT antibody tiragolumab and anti-PD-L1 antibody atezolizumab exhibited a significant benefit for treating NSCLC patients with high levels of PD-L1 [256,257,258], leading to US FDA to approve the tiragolumab/atezolizumab as the first-line treatment for metastatic NSCLC patients with PD-L1 positive but no EGFR or ALK mutations recently.